Non-opioid Anesthesia Based on Thoracic Paravertebral Block During Laparoscopic Sleeve Gastrectomy

Launched by IVO JURISIC · Jul 17, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a way to manage pain without using opioid medicines during weight-loss surgery called laparoscopic sleeve gastrectomy. Instead of opioids, which can cause side effects like drowsiness and breathing problems, this study uses a special type of pain relief called a thoracic paravertebral block. This technique involves injecting a numbing medicine near the nerves in the back to help block pain during and after surgery. The goal is to help patients recover faster, move more quickly after surgery, avoid nausea and vomiting, and control pain well without opioid side effects.

The study is open to adults with obesity who have been evaluated by a healthcare team and are scheduled for this type of weight-loss surgery. To join, patients should have a body mass index (BMI) of 30 or higher and be generally healthy enough for surgery (classified as ASA status 2-3). Some people won’t be eligible, including those with certain heart problems, infections near the injection site, allergies to the medicines, or other health issues that could interfere with the treatment or communication. Participants can expect careful monitoring during surgery, with pain control aimed at avoiding opioids, and if the surgery needs to be changed to an open procedure, pain relief will still be managed effectively without changing the approach.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • -. patients with a prior history of treatment by a multidisciplinary obesity team scheduled for laparoscopic sleeve gastrectomy (LSG)
• • body mass index of 30 kg/m² or greater
• • patients classified as ASA status 2-3.
• Exclusion Criteria:
• • allergies to the intended medications
• • patient refusal
• • uncontrolled psychiatric disorders
• • intracranial pathology
• • cerebrovascular damage
• • any factors impairing effective communication
• Additional Exclusion Criteria:
• 1. For patients receiving thoracic paravertebral block (TPVB):
• • - the presence of infection at the puncture site
• 2. For the OFA group:
• • 2nd or 3rd-degree atrioventricular block
• • bradycardia with a heart rate below 50 beats per minute
• • coronary artery disease,
• • cardiomyopathy.